FBR Remains Neutral on Alexion Pharma (ALXN); Sees Sales of Kanuma Continuing to Lag
Tweet Send to a Friend
FBR & Co. affirms Alexion Pharmaceuticals (Nasdaq: ALXN) at Market Perform with a price target of $130 after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
